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Purpose: To determine the incidence of chemotherapy-induced nausea/vomiting (CINV) and 
chemotherapy treatment delay and adherence among patients receiving palonosetron versus 
other 5-hydroxytryptamine receptor antagonist (5-HT
3
 RA) antiemetics.
Materials and methods: This retrospective claims analysis included adults with primary 
malignancies who initiated treatment consisting of single-day intravenous highly emetogenic 
chemotherapy (HEC) or moderately EC (MEC) regimens. Treatment delay was defined as a gap 
in treatment at least twice the National Comprehensive Cancer Network-specified cycle length, 
specific to each chemotherapy regimen. Treatment adherence was determined by the percentage 
of patients who received the regimen-specific recommended number of chemotherapy cycles 
within the recommended time frame.
Results: We identified 1,832 palonosetron and 2,387 other 5-HT
3
 RA (“other”) patients who 
initiated HEC therapy, and 1,350 palonosetron users and 1,379 patients on other antiemetics 
who initiated MEC therapy. Fewer patients receiving palonosetron experienced CINV versus 
other (HEC, 27.5% versus 32.2%, P=0.0011; MEC, 36.1% versus 41.7%, P=0.0026), and fewer 
treatment delays occurred among patients receiving palonosetron versus other (HEC, 3.2% versus 
6.0%, P,0.0001; MEC, 17.0% versus 26.8%, P,0.0001). Compared with the other cohort, 
patients receiving palonosetron were significantly more adherent to the index chemotherapy 
regimen with respect to the recommended time frame (HEC, 74.7% versus 69.7%, P=0.0004; 
MEC, 43.1% versus 37.3%, P=0.0019) and dosage (HEC, 27.3% versus 25.8%, P=0.0004; 
MEC, 15.0% versus 12.6%, P=0.0019).
Conclusion: Palonosetron more effectively reduced occurrence of CINV in patients receiv-
ing HEC or MEC compared with other agents in this real-world setting. Additionally, patients 
receiving palonosetron had better adherence and fewer treatment delays than patients receiving 
other 5-HT
3
 RAs.
Keywords: palonosetron, adherence, CINV, delay of therapy, observational, health services 
research
Introduction
Nausea and vomiting are common chemotherapy-associated side effects ranked by 
patients as especially distressing.1–7 Chemotherapy-induced nausea and vomiting 
(CINV) can cause psychological distress, nutritional deficiencies, and reduced qual-
ity of life among patients receiving chemotherapy.5–8 Furthermore, its occurrence 
may potentially affect adherence to chemotherapy regimens, leading to treatment 
delays or receipt of fewer treatments or lower dosages than recommended.9,10 Such 
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events may have an adverse effect on treatment efficacy, 
ultimately resulting in suboptimal clinical outcomes and 
potentially increased health care-related resource utiliza-
tion and costs.3
Recognizing the importance of preventing and manag-
ing CINV, leading oncology societies have issued treatment 
guidelines11–13,29 recommending 5-hydroxytryptamine-recep-
tor antagonists (5-HT
3
 RAs) as the preferred medication class 
to effectively prevent CINV in patients receiving highly eme-
togenic chemotherapy (HEC) or moderately EC (MEC).19,20 
Compared to the older agents, palonosetron – a newer 5-HT
3
 
RA – is pharmacologically distinct, with a longer half-life 
and greater receptor-binding affinity, allosteric binding to 
serotonin receptors with positive cooperativity, and cross 
talk with Neurokinin-1 (NK-1) receptors.21–23 While the early 
5-HT
3
 RA compounds were considered equally  efficacious,19 
palonosetron demonstrated greater efficacy than active com-
parators in preventing CINV in patients receiving HEC or 
MEC in multiple clinical trials.20,24–26 Hatoum et al compared 
palonosetron with other 5-HT
3
 RAs in a real-world setting 
among patients with breast/lung cancer undergoing cisplatin/
carboplatin treatments.19,27 They concluded that patients who 
received prophylaxis with palonosetron had a significantly 
lower risk of CINV events than those who had received other 
5-HT
3
 RA agents. Furthermore, those breast/lung cancer 
patients receiving palonosetron experienced 49.5% and 
29.1% fewer CINV days, respectively.27 Their study focused 
on serious CINV events resulting in hospital or emergency 
department admissions, and did not include CINV events 
occurring in an outpatient context. Craver et al found that 
prophylactic administration of palonosetron among patients 
with hematologic malignancies who were receiving HEC/
MEC resulted in a 20.4% decrease in CINV event rate per 
cycle compared with patients receiving other 5-HT
3
 RAs.28 
However, while 5-HT
3
 RA agents have been proven effective 
in preventing CINV, little is known regarding their impact 
on chemotherapy treatment adherence and delay. To address 
these questions, a real-world study was designed comparing 
patients who received palonosetron with those who received 
other 5-HT
3
 RAs on incidence of acute and delayed CINV 
and chemotherapy treatment delay and adherence. This study 
also contributes to the development of methods to assess 
medication adherence for intravenous (IV) agents.
Materials and methods
This was an observational nested case–control study 
using data from the HealthCore Integrated Research Data-
base (HIRDSM). The HIRD is an integrated medical and 
 pharmacy-claims and laboratory-result database of com-
mercially insured patients from 14 major commercial health 
plans across the US representing approximately 45 million 
patient-lives dating as far back as January 1, 2001.
Cohort creation
The index date was defined as the earliest medical or phar-
macy claim date for an IV HEC or MEC between January 1, 
2002 and October 31, 2010. All patients included in the 
study were adults ($18 years of age as of the index date) 
who had one or more medical claims with a diagnosis of 
primary malignant breast, lung, or colorectal neoplasm dur-
ing the baseline period, which was defined as the 12 months 
before the index date. All patients had continuous medical 
and pharmacy health plan eligibility for at least 12 months 
pre- and 12 months postindex date. Patients were excluded 
if they 1) had a secondary malignant neoplasm or primary 
neoplasms at multiple sites, 2) had preindex HEC or MEC 
claims, 3) initiated multiday chemotherapy, 4) received oral 
chemotherapy alone or in combination with an IV formula-
tion, 5) switched from a single-day-per-cycle chemotherapy 
regimen to multiday chemotherapy, or 6) had medical 
claim(s) for pregnancy, labor, or delivery in the 6 months 
postindex.
Lastly, in order to create clean comparison cohorts, 
patients receiving both palonosetron and any of the “other” 
5-HT
3
 RAs any time during the course of one or more chemo-
therapy treatment cycles were excluded from the analysis. The 
remaining patients were stratified into either the palonosetron 
or other 5-HT
3
 RA treatment cohorts. Specifically, patients 
in the palonosetron group received only palonosetron and no 
other IV 5-HT
3
 RA agent (ie, dolasetron, granisetron, and/or 
ondansetron; see Table S1) as prophylactic or rescue therapy 
beginning 1 day before through 5 days after the start of any 
chemotherapy treatment cycle; those in the other 5-HT
3
 RA 
cohort were allowed to receive any prophylactic 5-HT
3
 RA 
agent other than palonosetron.
assignment of chemotherapy regimens
Index HEC and MEC agents were defined as any chemothera-
peutic agent classified as having a known high or moderate 
emetogenic potential (Table S2).29 Chemotherapy agents 
were identified using generic product identifier (GPI) and 
Healthcare Common Procedure Coding System (HCPCS) 
codes. Chemotherapy dose determined the HEC/MEC status 
of certain chemotherapy drugs (eg, cyclophosphamide and 
cisplatin) by calculating the index dose administered and 
then applying the National Comprehensive Cancer Network® 
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(NCCN®)-recommended Guidelines available at the time of 
the study for classification (Table S3).29 Because only single-
day administration regimens were included in the study, the 
average dose was equal to the average strength, as noted on 
medical or pharmacy claims. Body-surface area (BSA) was 
not available on claim forms, so published BSA estimates of 
cancer patients were used to determine the average dose per 
square meter.30 The standard estimates used were 1.91 m2 for 
men (95% confidence interval [CI] 1.90–1.92) and 1.71 m2 
for women (95% CI 1.70–1.72).
For regimens involving a combination of chemotherapeu-
tic agents, the agent with the highest emetic risk defined the 
risk of the combination (ie, one MEC agent and one HEC 
agent equaled an HEC regimen; one lowly EC [LEC] and 
one MEC equaled an MEC regimen).12,13 Two MEC agents 
were classified as HEC; however, two LEC agents remained 
a lowly emetogenic regimen (Table 1).31 Additional informa-
tion on the step-by-step regimen identification can be found 
in the Supplementary materials.
Claims for index chemotherapy agents dated 7 days or 
later after the beginning of the cycle were designated as the 
beginning of the subsequent cycle, and so on until the end of 
the 12-month observation period. The end of a chemotherapy 
cycle was determined using either the passing of the NCCN-
recommended number of weeks between two cycles (Table 2), 
which was specific to each treatment regimen, or the start date of 
the subsequent treatment cycle, whichever occurred earlier.
Outcome measures
Acute CINV was identified by International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes for nausea and vomiting, persistent vomit-
ing, or volume depletion, or current procedural terminology 
codes for hydration, on the day of chemotherapy (Table S1). 
Delayed CINV was identified by the same ICD-9-CM and 
CPT codes for nausea and vomiting, volume depletion and 
hydration, as well as GPI/HCPCS codes for IV rescue medi-
cations (dexamethasone, fosaprepitant, diphenhydramine, 
 promethazine,  haloperidol, prochlorperazine, lorazepam, or 
metoclopramide) or 5-HT
3
 RAs (Table S1) between the day 
after chemotherapy and day 5 of the chemotherapy cycle 
of interest. CINV events were assessed on a patient- and 
cycle-level basis.
Each index chemotherapy regimen was assigned a total 
number of chemotherapy cycles and an allowed gap between 
chemotherapy cycles according to the recommendations of 
the 2011 NCCN Clinical Practice Guidelines In Oncology 
(NCCN Guidelines®) (Table 2).14–18 For example, a lung 
cancer patient on cisplatin (index dose of 100 mg/m2) and 
vinorelbine would be assumed to have initiated a therapy 
involving four treatment cycles with an allowed rest period 
of 4 weeks between each cycle.
Treatment delay was measured in two ways: 1) the pro-
portion of patients who delayed their index chemotherapy 
based on the presence of a significant gap between two che-
motherapy cycles, and 2) the mean and median time from the 
index date to the date of treatment delay. Delay of therapy 
was defined as a gap in treatment exceeding twice the NCCN-
specified cycle length specific to each chemotherapy regimen 
(Table 2). The date of treatment delay was the date of the last 
chemotherapy cycle start date prior to delay plus one cycle 
length. For patients on combination regimens, delay of any 
one agent involved in the regimen constituted delay of the 
entire regimen. We also performed a sensitivity analysis 
around the permissible treatment gap, assigning a lower 
limit of 1.5 times the NCCN-recommended cycle length 
and an upper limit of three times the NCCN-recommended 
cycle length.
Treatment adherence was measured in four related ways: 
the percentage of patients who received the 1) recommended 
number of cycles for their specific chemotherapy regimen, 
as determined by NCCN guidelines, 2) recommended num-
ber of chemotherapy cycles for their regimen within the 
recommended time frame, 3) recommended chemotherapy 
dose within a 10% margin, and 4) recommended number of 
cycles within the specified time frame at the expected dose. 
We used measure 2 as our primary measure of adherence. 
Patients on multiagent regimes were required to be adher-
ent with each component of the regimen to be considered 
adherent overall.
statistical analysis
Descriptive statistics were used to characterize the incidence 
of acute and delayed CINV, as well as baseline patient 
characteristics, such as primary cancer site and chemo-
therapy regimen. Means/standard deviations were used for 
Table 1 algorithm to identify heC and MeC regimens
Regimen makeup HEC/MEC classification 
of regimen
any heC drug heC
Two or more MeC drugs heC
One MeC drug with or without low or  
minimal emetogenic chemotherapy (leC)
MeC
Multiple leC drugs leC
Abbreviations: heC, highly emetogenic chemotherapy; MeC, moderately eC; 
leC, lowly eC; eC, emetogenic chemotherapy.
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Table 2 Chemotherapy index regimens
Index HEC/MEC regimen (± LEC) Emetogenicity Number of  
recommended  
cyclesa
Allowed  
gap  
(weeks)b
Regimen 
duration  
(weeks)
Breast cancer
Cyclophosphamide (600 mg/m2; with or without docetaxel) if index dose  
.1,500 mg/m2 then heCc; 
if index dose  
1,500 mg/m2 then MeCc
4 3 12
Cyclophosphamide (600 mg/m2)/doxorubicin (60 mg/m2) heCc 4 3 12
Cyclophosphamide (600 mg/m2)/doxorubicin (50 mg/m2) + docetaxel heCc 6 3 18
Cyclophosphamide (600 mg/m2)/doxorubicin (60 mg/m2) + docetaxel heCc 4 3 12
Cyclophosphamide (600 mg/m2)/doxorubicin (60 mg/m2) + paclitaxel (R1) heCc 4 2 8
Cyclophosphamide (600 mg/m2)/doxorubicin (60 mg/m2) + paclitaxel (R2) heCc 4 3 12
Cyclophosphamide (500 mg/m2)/doxorubicin (50 mg/m2) + 5-fluorouracil heCc 6 3 18
Cyclophosphamide (100 mg/m2)/epirubicin (830 mg/m2) heCc 8 3 24
Cyclophosphamide (500 mg/m2)/epirubicin (75 mg/m2) + 5-fluorouracil heCc 4 3 12
Cyclophosphamide (500 mg/m2)/epirubicin (100 mg/m2) + docetaxel +  
5-fluorouracil
heCc 6 3 18
Cyclophosphamide (600 mg/m2)/epirubicin (90 mg/m2) + paclitaxel + 
5-fluorouracil
heCc 4 3 12
Carboplatin (500–900 mg/m2; with docetaxel or trastuzumab or both) MeCc 6 3 18
Carboplatin (150 mg) + paclitaxel MeCc 3 1 3
Carboplatin (500 mg) + paclitaxel MeCc 3 3 9
Carboplatin (150–900 mg/m2) + gemcitabine MeCc 6 3 18
Lung cancer
Cisplatin (100 mg) + vinorelbine if index dose $50 mg/m2,  
then heCc; 
if index dose ,50 mg/m2,  
then MeCc
4 4 16
Cisplatin (75–80 mg) + vinorelbine 4 3 12
Cisplatin (75 mg/m2) + gemcitabine 4 3 12
Cisplatin (75 mg/m2) + docetaxel 4 3 12
Cisplatin (75 mg/m2) + etoposide 4 4 16
Cisplatin (75 mg/m2) + pemetrexed 4 3 12
Carboplatin (150–900 mg/m2) + etoposide MeCc 6 4 24
Carboplatin (150–900 mg/m2) + gemcitabine MeCc 6 3 18
Carboplatin (500–900 mg/m2) + docetaxel MeCc 6 3 18
Carboplatin (500–900 mg) + paclitaxel MeCc 3 3 9
Carboplatin (150–900 mg) + paclitaxel MeCc 3 1 3
Colorectal cancer
Oxaliplatin (85 mg/m2) + 5-fluorouracil MeCc 12 2 24
Oxaliplatin (85 mg/m2) + 5-fluorouracil + leucovorin MeCc 12 2 24
Oxaliplatin (130 mg/m2) + capecitabine MeCc 8 3 24
Notes: aas per nCCn guidelines at the time of the study14–18 (the most recent NCCN guidelines indicate minor changes to the emetogenicity classification); bequal to the 
recommended cycle length as per nCCn guidelines14–18; chesketh rule in effect.31 Referenced with permission from the nCCn Clinical Practice guidelines in Oncology 
(nCCn guidelines®) for Breast Cancer V2.2011, Colon Cancer V3.2011, Rectal Cancer V4.2011, small Cell lung Cancer V2.2012, non-small Cell lung Cancer V3.2011. 
© national Comprehensive Cancer network, inc 2015. all rights reserved. all accessed July 11, 2011. To view the most recent and complete version of the guidelines, go 
online to nCCn.org. naTiOnal COMPRehensiVe CanCeR neTWORK®, nCCn®, nCCn gUiDelines®, and all other nCCn Content are trademarks owned by 
the national Comprehensive Cancer network, inc.
Abbreviations: heC, highly emetogenic chemotherapy; MeC, moderately eC; leC, lowly eC; eC, emetogenic chemotherapy; nCCn, national Comprehensive Cancer network.
continuous data, and counts/relative frequencies were used 
for  categorical data. Each baseline characteristic and study 
outcome was compared using unadjusted statistical tests 
between patients receiving palonosetron and those receiving 
all other 5-HT
3
 RAs. Continuous variables were compared 
using Student’s t-test or Wilcoxon rank-sum test, depending 
on the distributional characteristics. Categorical data were 
compared using χ2 tests.
Logistic regression models were used to estimate asso-
ciations between antiemetic treatment (palonosetron versus 
other 5-HT
3
 RAs) and CINV (acute and/or delayed), delay of 
index chemotherapy regimen, and adherence to index che-
motherapy regimen. Covariates in the multivariable regres-
sion analysis included age, sex, geographic region, health 
plan type, year of index date, cancer type, Deyo–Charlson 
Comorbidity Index (DCI) score,32 individual comorbidities, 
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and baseline receipt of LEC, radiation, and antiemetics. All 
analyses were stratified by HEC and MEC regimens.
Results
Patient characteristics
We identif ied 1,832 HEC patients who received only 
palonosetron and no other 5-HT
3
 RA and 2,387 HEC patients 
who received other 5-HT
3
 RAs excluding palonosetron 
(Table 3). In the HEC group, the mean age was slightly higher 
among palonosetron users (52.0 versus 51.4 years for those 
receiving other 5-HT
3
 RAs, P=0.0345), and breast cancer 
was the most common malignancy (97.3% palonosetron and 
96.0% other 5-HT
3
 RAs). The mean baseline DCI scores 
were 4.35 for patients receiving palonosetron and 4.56 for 
those receiving other 5-HT
3
 RAs (P=0.0211). Similarly, we 
identified 1,350 palonosetron users and 1,379 other 5-HT
3
 RA 
recipients who indexed on an MEC therapy. Within the MEC 
cohort, the mean age and DCI scores were slightly lower 
among palonosetron patients compared to those receiving 
other 5-HT
3
 RAs (56.8 versus 59.2 years, P,0.0001; 4.29 
versus 4.55, P=0.0229; respectively). Breast (48.6%) and 
colon (29.3%) cancers were the most prevalent malignan-
cies among palonosetron recipients, whereas lung (35.2%) 
and colon (34.0%) cancers were more common among those 
receiving other 5-HT
3
 RAs in the MEC group.
incidence of CinV
Within the HEC cohort, fewer palonosetron patients experi-
enced CINV compared with those who received other 5-HT
3
 
RAs (27.5% versus 32.2%, P=0.001; Table 4). Likewise, 
19.1% and 14.8% of HEC patients receiving palonosetron 
experienced $1 acute and $1 delayed CINV event(s) 
respectively, compared to 20.5% and 20.2% of other 5-HT
3
 
RA HEC patients. Furthermore, patients in the other 5-HT
3
 
RA group experienced more CINV events per cycle than the 
palonosetron group (0.3 versus 0.2 events/cycle). In the MEC 
cohort, fewer palonosetron patients experienced CINV and 
CINV events per cycle compared with those who received 
other 5-HT
3
 RAs (36.1% versus 41.7%, P=0.003; 0.3 versus 
0.4 events/cycle). MEC patients in the palonosetron cohort 
were significantly less likely to experience delayed CINV 
versus patients in the other 5-HT
3
 RA cohort (20.6% versus 
29.5%, P,0.0001).
Chemotherapy treatment delay
Fewer chemotherapy treatment delays occurred among 
patients receiving palonosetron compared with other 5-HT
3
 
RAs in both the HEC (3.2% versus 6.0%, P,0.0001) and 
MEC (17.0% versus 26.8%, P,0.0001) cohorts (Table 4). 
The results for delayed therapy remained consistent when 
using the upper and lower limits as defined earlier (see 
Table 4). Mean time to delay was similar across the palonose-
tron and other 5-HT
3
 RAs groups (approximately 76 days in 
the HEC cohort and 86 days in the MEC cohort).
Chemotherapy treatment adherence
In both the HEC and MEC cohorts, more patients receiving 
palonosetron were adherent to their chemotherapy regimen 
compared to those who received other 5-HT
3
 RAs for three 
of the four different adherence measures. In the HEC cohort, 
slightly more of those who received palonosetron completed 
the recommended number of chemotherapy cycles versus 
those who received other 5-HT
3
 RAs (87.7% versus 86.4%, 
respectively; P=0.2022). The difference was greater in the 
MEC cohort, with 65.6% of those receiving palonosetron and 
59.8% of those receiving other 5-HT
3
 RAs completing the 
recommended number of chemotherapy cycles (P=0.0017). 
Compared with those who received other 5-HT
3
 RAs, sig-
nificantly more patients receiving palonosetron completed 
the recommended number of chemotherapy cycles within 
the specified time frame (HEC, 74.7% versus 69.7%, respec-
tively, P=0.0004; MEC, 43.1% versus 37.3%, respectively, 
P=0.0019) and at the expected doses (HEC, 27.3% versus 
25.8%, respectively, P=0.0004; MEC, 15.0% versus 12.6%, 
respectively, P=0.0019) (Table 4). A similar proportion of 
patients in both the palonosetron and other 5-HT
3
 RA cohorts 
received the recommended chemotherapy doses for HEC 
(33.6% palonosetron and 33.4% other 5-HT
3
 RAs, P=0.8951) 
and MEC regimens (34.6% palonosetron and 37.1% other 
5-HT
3
 RAs, P=0.1673).
These findings were supported in a multivariable analysis 
(Figure 1). Treatment with palonosetron was associated with 
a reduced likelihood of CINV occurrence in the HEC (odds 
ratio [OR] 0.82, 95% CI 0.71–0.95) and MEC (OR 0.77, 
95% CI 0.65–0.92) cohorts. Palonosetron treatment was also 
associated with fewer chemotherapy treatment delays in both 
cohorts (HEC, OR 0.63, 95% CI, 0.45–0.87; MEC, OR 0.74, 
95% CI 0.60–0.91). Although palonosetron was associated 
with greater chemotherapy adherence in the HEC cohort 
(OR 1.25, 95% CI 1.07–1.45), no association was found in 
the MEC cohort (OR 1.1, 95% CI 0.92–1.32).
Discussion
In this retrospective, observational, nested case–control study, 
patients who received prophylactic or rescue palonosetron 
had significantly fewer CINV events, fewer chemotherapy 
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Table 3 Palonosetron versus other 5-hT3 Ras among patients initiating an heC/MeC regimen
Characteristics HEC MEC
Palonosetron  
groupa 
n=1,832
Other 5-HT3  
RA groupb 
n=2,387
P-value Palonosetron  
groupa 
n=1,350
Other 5-HT3  
RA groupb 
n=1,379
P-value
Female, n (%) 1,805 (98.5) 2,333 (97.7) 0.0643 981 (72.7) 857 (62.2) ,0.0001
age at index (years), mean ± sD 52.04 (±9.52) 51.41 (±9.6) 0.0345 56.82 (±10.9) 59.21 (±11.33) ,0.0001
 18–44 394 (21.5) 571 (23.9) 0.1046 175 (13.0) 144 (10.4) ,0.0001
 45–64 1,276 (69.7) 1,632 (68.4) 858 (63.6) 804 (58.3)
 $65 162 (8.8) 184 (7.7) 317 (23.5) 431 (31.3)
geographic region, n (%)       
 northeast 288 (15.7) 278 (11.7) ,0.0001 185 (13.7) 173 (12.6) ,0.0001
 south 585 (31.9) 736 (30.8) 445 (33.0) 480 (34.8)
 Midwest 651 (35.5) 488 (20.4) 485 (35.9) 406 (29.4)
 West 232 (12.7) 773 (32.4) 172 (12.7) 276 (20.0)
 Unknown 76 (4.2) 112 (4.7) 63 (4.7) 44 (3.2)
health plan type, n (%)       
 hMO 314 (17.1) 487 (20.4) 0.0047 238 (17.6) 278 (20.2) 0.0115
 POs 99 (5.4) 85 (3.6) 49 (3.6) 34 (2.5)
 PPO 1,286 (70.2) 1,661 (69.6) 898 (66.5) 879 (63.7)
 FFs 12 (0.7) 15 (0.6) 7 (0.5) 21 (1.5)
 Other/unknown 121 (6.6) 139 (5.8) 158 (11.7) 167 (12.1)
 Medicare planc 134 (7.3) 190 (8.0) 0.4352 233 (17.3) 353 (25.6) ,0.0001
index year, n (%)       
 2002–2004 16 (0.9) 736 (30.8) ,0.0001 8 (0.6) 105 (7.6) ,0.0001
 2005–2006 936 (51.1) 924 (38.7) 343 (25.4) 515 (37.4)
 2007–2008 854 (46.6) 670 (28.1) 963 (71.3) 685 (49.7)
 2009–2011 26 (1.4) 57 (2.4) 36 (2.7) 74 (5.4)
Baseline medical conditions, n (%)       
 Breast cancer 1,782 (97.3) 2,291 (96.0) 0.0228 656 (48.6) 425 (30.8) ,0.0001
 lung cancer 50 (2.7) 96 (4.0) 0.0228 299 (22.2) 485 (35.2) ,0.0001
 Colorectal cancer 0 0 na 395 (29.26) 469 (34.0) 0.0076
 hypertension 679 (37.1) 871 (36.5) 0.7015 700 (51.9) 751 (54.5) 0.1722
 Cerebrovascular disease 33 (1.8) 47 (2.0) 0.6922 80 (5.9) 101 (7.3) 0.1422
 heart failure 26 (1.4) 39 (1.6) 0.5748 49 (3.6) 76 (5.5) 0.0187
 Renal diseased 35 (1.9) 46 (1.9) 0.9689 60 (4.4) 63 (4.6) 0.8759
 liver disease 28 (1.5) 34 (1.4) 0.7808 40 (3.0) 36 (2.6) 0.5759
 Diabetes mellitus 174 (9.5) 194 (8.1) 0.1179 216 (16) 226 (16.4) 0.7829
 ischemic heart disease 84 (4.6) 107 (4.5) 0.8738 165 (12.2) 238 (17.3) 0.0002
 Pulmonary diseasee 211 (11.5) 297 (12.4) 0.3602 315 (23.3) 460 (33.4) ,0.0001
 Osteoporosis 197 (10.8) 244 (10.2) 0.5761 149 (11.0) 149 (10.8) 0.8459
 Mental health disorder 441 (24.1) 543 (22.8) 0.3135 352 (26.1) 375 (27.2) 0.5083
DCi score       
 Mean ± sD 4.35 (±2.92) 4.56 (±2.98) 0.0211 4.29 (±2.88) 4.55 (±2.95) 0.0229
 Median (Q1–Q3) 2 (2–8) 3 (2–8) 0.0264 3 (2–8) 3 (2–8) 0.0002
Baseline therapies, n (%)       
 leC 93 (5.1) 108 (4.5) 0.4042 193 (14.3) 205 (14.9) 0.6734
 Radiation 60 (3.3) 113 (4.7) 0.0179 237 (17.6) 290 (21.0) 0.0215
 5-hT3 antiemetics 675 (36.8) 895 (37.5) 0.6652 450 (33.3) 374 (27.1) 0.0004
 non-5-hT3 antiemetics 1,166 (63.7) 1,359 (56.9) ,0.0001 828 (61.3) 728 (52.8) ,0.0001
Chemotherapeutic regimens, n (%)       
 Cyclophosphamide 6 (0.3) 7 (0.3)  499 (37.0) 287 (20.8)  
 Cyclophosphamide/doxorubicin 1,656 (90.4) 2,133 (89.4)   
 Cyclophosphamide/epirubicin 120 (6.6) 151 (6.3)   
 Cisplatin 50 (2.7) 96 (4.0) 21 (1.6) 13 (0.9)
 Carboplatin    435 (32.2) 610 (44.2)
 Oxaliplatin    395 (29.3) 469 (34.0)
(Continued)
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Table 3 (Continued)
Characteristics HEC MEC
Palonosetron  
groupa 
n=1,832
Other 5-HT3  
RA groupb 
n=2,387
P-value Palonosetron  
groupa 
n=1,350
Other 5-HT3  
RA groupb 
n=1,379
P-value
Duration of study follow-up, days       
 Mean ± sD 1,239.79 (±521.83) 1,398.59 (±722.88) ,0.0001 1,036.1 (±414.11) 1,089.16 (±517.92) 0.0031
 Median (Q1–Q3) 1,200 (835.5–1,648.5) 1,295 (807–1,885) ,0.0001 994.5 (716–1,270) 1,013 (648–1,407) 0.1939
Notes: aReceipt of palonosetron and no other 5-hT3 Ra during any cycle, measured from (heC cycle-start date -1 day) until (heC cycle-start date +5 days); breceipt of any 
5-hT3 Ra except palonosetron during any cycle, measured from (chemotherapy cycle-start date -1 day) until (chemotherapy cycle start date +5 days); cconsisting of Medicare 
advantage, supplemental, and Part D plans; drenal disease included kidney disease, nephrosis, nephritis, and renal function impairment, including dialysis; epulmonary disease 
included asthma, bronchitis, pneumonia, emphysema, and COPD.
Abbreviations: hT, hydroxytryptamine; Ras, receptor antagonists; heC, highly eC; MeC, moderately eC; leC, lowly eC; neC, non-eC; eC, emetogenic chemotherapy; 
sD, standard deviation; hMO, health maintenance organization; POs, point of service; PPO, preferred provider organization; FFs, fee for service; na, not applicable; 
Q, quartile; COPD, chronic obstructive pulmonary disease; DCi, Deyo–Charlson Comorbidity index.
Table 4 Outcomes among palonosetron versus other 5-hT3 Ras in patients initiating an heC/MeC regimen
Outcomes of interest HEC MEC
Palonosetron  
group 
n=1,832
Other 5-HT3  
RA group 
n=2,387
P-value Palonosetron  
group 
n=1,350
Other 5-HT3  
RA group 
n=1,379
P-value
CinV       
 Patients experiencing $1 CinV event, n (%) 504 (27.5) 768 (32.2) 0.0011 487 (36.1) 575 (41.7) 0.0026
 Patients experiencing $1 acute CinV event 350 (19.1) 490 (20.53) 0.2513 361 (26.74) 334 (24.22) 0.1308
 Patients experiencing $1 delayed CinV event 271 (14.79) 482 (20.19) ,0.0001 278 (20.59) 407 (29.51) ,0.0001
 Total number of cycles 7,616 9,878  7,952 8,749  
 Total number of events 1,552 2,685  2,070 3,686  
 acute 769 1,212  1,193 1,196  
 Delayed 783 1,473  877 2,490  
 events/cycle 0.2038 0.2718  0.2603 0.4213  
Treatment delay       
 Treatment delay, n (%) 59 (3.2) 144 (6.0) ,0.0001 230 (17.0) 369 (26.8) ,0.0001
 Treatment delay, lower limit, n (%) 102 (5.6) 199 (8.3) 0.0005 363 (26.9) 536 (38.9) ,0.0001
 Treatment delay, upper limit, n (%) 19 (1.0) 40 (1.7) 0.08 101 (7.5) 163 (11.8) 0.0001
Therapy length until delay (days)      
 Mean (± sD) 76.28 (±22.65) 76.32 (±22.62) 0.9577 87.38 (±42.45) 85.45 (±48.18) 0.2659
 Median (Q1–Q3) 67 (64–85) 76 (64–85) 0.0147 85 (62–111) 85 (48–126) 0.0147
Treatment adherence, n(%)     
 Receipt of     
 1. Recommended number of cycles 1,607 (87.7) 2,062 (86.4) 0.2022 885 (65.6) 824 (59.8) 0.0017
 2.  Recommended number of cycles within  
the specified time frame
1,368 (74.7) 1,664 (69.7) 0.0004 582 (43.1) 514 (37.3) 0.0019
 3.  Recommended number of cycles within  
the specified time frame at the expected dose
500 (27.3) 616 (25.8) 0.0004 202 (15.0) 173 (12.6) 0.0019
 4. Recommended dose 616 (33.6) 798 (33.4) 0.8951 467 (34.6) 512 (37.1) 0.1673
Abbreviations: hT, hydroxytryptamine; Ras, receptor antagonists; heC, highly eC; MeC, moderately eC; eC, emetogenic chemotherapy; CinV, chemotherapy-induced 
nausea/vomiting; sD, standard deviation; Q, quartile.
treatment delays, and higher adherence to their chemotherapy 
regimen compared with patients who received any other IV 
5-HT
3
 RA medication. These findings were seen both among 
patients who were undergoing HEC treatment and those 
undergoing MEC treatment.
Results from clinical trials have demonstrated the over-
all efficacy of palonosetron in preventing acute CINV in 
patients receiving HEC and in preventing acute or delayed 
CINV in patients receiving MEC.20,24–26 However, limited 
evidence is available regarding the effect of palonosetron on 
chemotherapy adherence and treatment delay in a real-world 
setting. To our knowledge, no previous study has evaluated 
this association. A previous administrative claims analysis 
evaluated the risk of serious CINV events associated with 
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HEC: CINV incidence
MEC: adherence
0.15 0.25 0.35 0.45 0.55 0.65
Odds ratio
0.75 0.85 0.95 1.05 1.15 1.25 1.35 1.45 1.55 1.65
HEC: adherence
MEC: delay of therapy
HEC: delay of therapy
MEC: CINV incidence
Figure 1 Odds ratios and 95% confidence intervals for palonosetron versus other 5-HT3-Ras.
Notes: For CinV and delayed therapy, an odds ratio ,1 is associated with improved outcomes; for adherence, an odds ratio .1 is associated with improved outcomes.
Abbreviations: hT, hydroxytryptamine; CinV, chemotherapy-induced nausea/vomiting; heC, highly eC; MeC, moderately eC; eC, emetogenic chemotherapy.
hospital or emergency department admissions among patients 
with breast or lung cancer undergoing MEC or HEC who 
received palonosetron compared with those who received 
any other 5-HT
3
 RA.19 Patients receiving palonosetron 
experienced a significantly reduced risk of serious CINV 
compared to those who received other 5-HT
3
 RAs, ranging 
from 31% to 45% among lung and breast cancer patients, 
respectively. Another recent study by Craver et al evaluated 
the risk of CINV among recipients of palonosetron versus 
other 5-HT
3
 RAs initiating HEC/MEC therapy in all medical 
settings,28 using a broader definition of CINV encompassing 
events occurring any time within 7 days of the chemotherapy 
cycle-start date. While both studies showed a reduction in 
CINV with palonosetron use as expected, an exploration of 
the effect of CINV risk reduction on chemotherapy adherence 
or delay was not conducted.
The real-world analysis in the current study demon-
strated improved adherence to chemotherapy regimens 
among patients who received palonosetron compared with 
other 5-HT
3
 RA agents. The association between the use of 
antiemetics and adherence may have been underestimated: 
patients undergoing chemotherapy, particularly HEC, are 
more likely to have been prepared by their health care pro-
viders to expect nausea and vomiting; such preparedness has 
been shown to alleviate the reported incidence of nausea and 
vomiting in patients receiving chemotherapy.31  Additionally, 
some patients undergoing IV chemotherapy regimens will 
have advanced disease, and may therefore not have the option 
of delaying or discontinuing treatment because of nausea 
and vomiting.33
Future research exploring the association between 
reduced CINV and chemotherapy adherence would benefit 
from a cost analysis, which was not included in the current 
study. A therapy that improves chemotherapy adherence by 
reducing CINV events could potentially reduce costs, both 
direct (costs of antiemetic medications, physician visits, and 
hospitalizations) and indirect (lost workdays and intangibles, 
including lower quality of life and potential consequences of 
delayed or reduced chemotherapy treatment). Other chemo-
therapy-associated side effects, such as fatigue, insomnia, or 
dermatologic conditions, which cannot be easily identified 
through claims, may also affect treatment adherence.
The nature of the administrative claims database and the 
lack of granularity precluded us from identifying more than 
one CINV event per day or the severity of the CINV expe-
rienced. While our approach to identify CINV events from 
claims matches that used in clinical trials of  antiemetics,19,28 
others have used criteria that were either more strict (eg, 
nausea, vomiting, and dehydration associated with hospital 
admissions27) or that relied on patient diaries rather than 
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diagnosis codes.24,25 The strategy used in the current study to 
define CINV did not capture patients using oral antiemetics 
or over-the-counter remedies, and the IV antiemetics may 
have been prescribed for reasons other than CINV (eg, for 
nausea and vomiting associated with migraine,34 surgery,35 or 
gastroparesis36). Nausea and vomiting occurring after day 5 of 
the chemotherapy cycle and before the subsequent cycle were 
not attributed to chemotherapy, and may have resulted in an 
underestimation of CINV events. Despite these limitations, 
the narrow time frame and broader medical setting used for 
identifying CINV in the current study design resulted in a 
conservative estimate of the impact of palonosetron and other 
5-HT
3
 RAs on CINV in a real-world setting.
Administrative claims are designed for reimbursement 
rather than research, and may contain coding errors or 
omissions. Therefore, the claim-based algorithm developed 
to identify patients with early stage cancers may be suscep-
tible to potential misidentification. Furthermore, standard 
definitions of adherence with IV chemotherapy regimens 
within an administrative claim database are lacking in the 
published literature. All patients were members of large 
commercial health plans in the US; the results may not 
be generalizable to patients outside the US or with other 
types of health insurance. While enrollment was limited to 
patients with single-day chemotherapy regimens, further 
research in patients receiving multiday regimens would be 
desirable. Because of concerns regarding patient selection 
and cohort size, the comparative analysis was limited to 
IV chemotherapy in general and IV 5-HT
3
 RAs as a class. 
Consistent with NCCN guideline recommendations, the 
analysis assumed that the non-5-HT
3
 RA components of 
the observed antiemetic regimens were similar across the 
palonosetron and other cohorts. NCCN guidelines were 
used to define chemotherapy regimens for this analysis, and 
did not allow for individualized treatment plans. BSA was 
needed to calculate the index dosage of cyclophosphamide 
and cisplatin; however, this information is unavailable in 
administrative claims. In the absence of US-based data, 
BSA estimates developed in a prior UK study30 were used 
to calculate index doses.
Conclusion
In this real-world retrospective analysis, patients receiving 
palonosetron were more adherent to their HEC/MEC regi-
mens and experienced fewer treatment delays compared to 
patients receiving other 5-HT
3
 RAs. Palonosetron was also 
associated with a decrease in the occurrence of CINV events. 
These results highlight the importance of symptom control in 
the context of adherence to prescribed chemotherapy, which 
may ultimately influence treatment and disease outcomes, 
including costs. This study also presents an innovative 
approach to estimate adherence to IV chemotherapy using 
administrative claims data.
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Supplementary materials
assignment of index chemotherapy 
regimens
Identification of chemotherapeutic regimens involves a two-
step process. Step one involves the identification of the highly 
emetogenic chemotherapy (HEC)/moderately EC (MEC) 
agents making up the regimen, which are identified within 6 
days of the index date. For instance, for a breast cancer patient 
with a claim for cyclophosphamide on the index date (ie, 
the start date of the first chemotherapy cycle), medical and 
pharmacy claims are evaluated to determine the presence of 
another HEC/MEC drug (eg, doxorubicin, epirubicin, etc). 
If no other HEC/MEC drug is found, then the index dose 
is calculated by using the strength (as determined from the 
index medical or pharmacy claim) and the body surface-
area estimate. A dose of .1,500 mg/m2 indicates receipt of 
HEC, while an index dose 1,500 mg/m2 indicates MEC. 
However, if doxorubicin is present, then the patient is clas-
sified as HEC as per the Hesketh algorithm.31 Step two of 
the chemotherapy-regimen identification involves claims for 
non-HEC/MEC chemotherapy agents also observed within 
Table S1 CinV codes and antiemetic therapies
Generic name GPI HCPCS ICD-9-CM 
diagnosis
5-HT3 RAs
Dolasetron mesylate 50250025x J1260, Q0180
granisetron 50250035x J1626, Q0166
Ondansetron 50250065x J2405, Q0179
Palonosetron 50250070x J2469
Other antiemetics
Dexamethasone 22100020x J1094, J1100, J7637, J7638, J7312, J8540
Fosaprepitant 502800351021x J1453
Promethazine 41400020101210, 414000201020x, 414000201003x,  
41400020101215, 414000201029x, 414000201052x
J2550, J2180, Q0169, Q0170
Prochlorperazine 59200055x J0780, Q0164, Q165, s0183
Metoclopramide 523000201020x, 523000201003x, 523000201012x,  
523000201013x, 523000201029x, 523000201072x,  
5230002011x
J2765
lorazepam 571000600020x, 571000600003x, 571000600013x J2060
haloperidol 5910001030x, 591000102020x, 5910001010x,  
591000102013x
J1630, J1631
Diphenhydramine 4120003010x, 412000303x, 60300020x, 6030990x J1200, Q0163
Nausea
nausea and vomiting 22100020x J1094, J1100, J7637, J7638, J7312, J8540 787.0x
Persistent vomiting 5028002000x J8501 536.2x
Volume depletion 502800351021x J1453 276.5x
hydration (nontherapeutic  
administration)
96360, 96361, 90760, 90761, 2018F, g0345
Abbreviations: CINV, chemotherapy-induced nausea/vomiting; HT, hydroxytryptamine; RAs, receptor antagonists; GPI, generic product identifier; HCPCS, Healthcare 
Common Procedure Coding System; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification.
6 days of the index date (Table S3). In the aforementioned 
example, for a patient indexing on cyclophosphamide and 
doxorubicin, if a claim for another lowly EC or non-EC drug 
(eg, docetaxel, paclitaxel, etc) is found within ±6 days of the 
index date, then the patient’s adherence will be evaluated as 
per the NCCN Guidelines® recommendations for the appro-
priate cyclophosphamide/doxorubicin/docetaxel combination 
regimen. Where multiple regimen options were available 
for the drugs involved, additional analysis was performed to 
determine the specific regimen. This included determining the 
doses of the HEC/MEC components in order to pinpoint the 
specific regimen. For example, a doxorubicin dose of 50 and 
60 mg/m2 would indicate a regimen involving six and four 
cycles, respectively (Table 2). Duration between the claims 
for the index HEC/MEC drugs was also used if the doses 
were insufficient in differentiating among the various regi-
men options. A combination involving cyclophosphamide/
doxorubicin/paclitaxel could be assigned a regimen either 
8 weeks or 12 weeks long if the gap between the first and 
second claim for cyclophosphamide/doxorubicin was found 
to be 14 or 21 days, respectively.
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Table S2 Chemotherapy codes and emetogenic potential
Description GPI code HCPCS code Emetogenicity Formulation
Carmustine 21102010x J9050, C9437 Other iV
Cisplatin 211000200020x J9060, J9062, C9418 Other iV
Dacarbazine 2170002000x J9130, J9140, C9423 heC iV
Mechlorethamine 211010301021x J9230 heC iV
streptozotocin 21102030002105 J9320 heC iV
alemtuzumab 21353010x J9010 Minimal iV
arsenic trioxide 21700008x J9017 MeC iV
azacitidine 21300003x J9025 MeC iV
Bendamustine 21100009x J9033 MeC iV
Carboplatin 21100015x J9045 MeC iV
Clofarabine 21300008x J9027, C9129 MeC iV
Dactinomycin 212000200021x J9120 MeC iV
Daunorubicin 21200030x J9150–J9151, C9424 MeC iV
Doxorubicin 21200040x J9000–J9001, C9415 Other iV
epirubicin 21200042x J9178, J9180 Other iV
idarubicin 21200045x J9211, C9429 MeC iV
ifosfamide 2110102500x, 219900024064x J9208, C9427 Other iV
irinotecan 21550040x J9206 MeC iV
Melphalan 211010400021x, 211010401021x J9245 MeC iV
Oxaliplatin 21100028x J9263, C9205 MeC iV
Temozolomide 211040700021x J9328, C9253 MeC iV
aldesleukin 21703020x J9015 Other iV
amifostine crystalline 21758010x J0207 Other iV
Cyclophosphamide 21101020002x J9070–J9097, C9420, C9421 Other iV
Cytarabine 21300010x J9098–J9110, C9422 Other iV
interferon-α 217000601x, 217000602x, 217000603x J9212–J9215 Other iV
altretamine 21100005x  MeC/heC Oral
Procarbazine 21700050x s0182 MeC/heC Oral
Cyclophosphamide 211010200003x J8530 Other Oral
imatinib 21534035x s0088 Minimal/low Oral
Temozolomide 211040700001x J8700 Other Oral
Busulfan 211000100003x J0594, J8510 Other Oral
estramustine phosphate sodium 2140302010x  MeC/heC Oral
etoposide 21500010x J8560 MeC/heC Oral
lomustine 211020200001x s0178 MeC/heC Oral
Notes: Referenced with permission from the nCCn Clinical Practice guidelines in Oncology (nCCn guidelines®) for antiemesis, Version 1.2012. © national 
Comprehensive Cancer network, inc 2015. all rights reserved. accessed august 11, 2011. To view the most recent and complete version of the guideline, go online to 
nCCn.org. naTiOnal COMPRehensiVe CanCeR neTWORK®, nCCn®, nCCn gUiDelines®, and all other nCCn Content are trademarks owned by the national 
Comprehensive Cancer network, inc. Other = nCCn emetogenicity rating depends on dosage.
Abbreviations: GPI, generic product identifier; HCPCS, Healthcare Common Procedure Coding System; HEC, highly EC; MEC, moderately EC; EC, emetogenic 
chemotherapy; iV, intravenous.
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Table S3 heC/MeC regimens
Agent Regimen Schedule Regimen type MEC/HEC
Cyclophosphamide TC • Cyclophosphamide 600 mg/m2 iV day 1 
Cycled every 3 weeks for four cycles
single day Depends on dosage
Cyclophosphamide/ 
doxorubicin
TaC (with docetaxel) •  Doxorubicin 50 mg/m2 iV day 1 
•  Cyclophosphamide 500 mg/m2 iV day 1 
Cycled every 3 weeks for six cycles
single day heC
TaC (with docetaxel) •  Doxorubicin 60 mg/m2 on day 1 
•  Cyclophosphamide 500 mg/m2 iV day 1 
Cycled every 3 weeks for four cycles
single day heC
aC •  Doxorubicin 60 mg/m2 iV day 1 
•  Cyclophosphamide 600 mg/m2 iV day 1 
Cycled every 2 weeks for four cycles
single day heC
•  Doxorubicin 60 mg/m2 iV day 1 
•  Cyclophosphamide 600 mg/m2 iV day 1 
Cycled every 3 weeks for four cycles
single day heC
•  Doxorubicin 60 mg/m2 iV day 1 
•  Cyclophosphamide 600 mg/m2 iV day 1 
Cycled every 3 weeks for four cycles
single day heC
•  Doxorubicin 60 mg/m2 iV day 1 
•  Cyclophosphamide 600 mg/m2 iV day 1 
Cycled every 3 weeks for four cycles
single day heC
FaC/CaF (with 5-FU) •  Doxorubicin 50 mg/m2 iV day 1 
•  Cyclophosphamide 500 mg/m2 iV day 1 
Cycled every 3 weeks for six cycles
single day heC
Cyclophosphamide/ 
epirubicin
FeC/CeF (with 5-FU) •  epirubicin 75 mg/m2 iV day 1 
•  Cyclophosphamide 500 mg/m2 day 1 
Cycled every 3 weeks for four cycles
single day heC
eC •  epirubicin 100 mg/m2 iV day 1 
•  Cyclophosphamide 830 mg/m2 iV day 1 
Cycled every 3 weeks for eight cycles
single day heC
FeC •  epirubicin 100 mg/m2 iV day 1 
•  Cyclophosphamide 500 mg/m2 day 1 
Cycled every 3 weeks for three cycles
single day heC
FeC •  epirubicin 90 mg/m2 iV day 1 
•  Cyclophosphamide 600 mg/m2 iV day 1 
Cycled every 3 weeks for four cycles
single day heC
Carboplatin TCh •  Carboplatin aUC 6 iV day 1 
Cycled every 3 weeks for six cycles
single day MeC
Ch (with trastuzumab) •  Carboplatin aUC 6 iV day 1 
Cycled every 3 weeks for six cycles
single day MeC
CT (with docetaxel) •  Carboplatin aUC 6 iV day 1 
Cycled every 3 weeks for six cycles
single day MeC
Cisplatin CV (with vinorelbine) •  Cisplatin 100 mg/m2 day 1 
Cycled every 4 weeks for four cycles
single day heC/depends on dosage
CV (with vinorelbine) •  Cisplatin 75–80 mg/m2 day 1 
Cycled every 3 weeks for four cycles
single day heC/depends on dosage
Cg (with gemcitabine) •  Cisplatin 75 mg/m2 day 1 
Cycled every 3 weeks for four to six cycles
single day heC/depends on dosage
CD (with docetaxel) •  Cisplatin 75 mg/m2 day 1 
Cycled every 3 weeks for four to six cycles
single day heC/depends on dosage
CP (with pemetrexed) •  Cisplatin 75 mg/m2 day 1 
Cycled every 3 weeks for four cycles
single day heC/depends on dosage
Carboplatin PC (with paclitaxel) •  Carboplatin aUC 6 day 1 
Cycled every 3 weeks for four to six cycles
single day MeC
PC (with paclitaxel) •  Carboplatin aUC 2 (initial) and 6 (last 2) weekly 
Total of three cycles
single day MeC
(Continued)
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Table S3 (Continued)
Agent Regimen Schedule Regimen type MEC/HEC
Pg (with gemcitabine) •  Carboplatin aUC 2 day 1 
Cycled every 3 weeks for six cycles
single day MeC
Pe (with etoposide) •  Carboplatin aUC 2 day 1 
Cycled every 4 weeks for six cycles
single day MeC
Oxaliplatin FOlFOX •  Oxaliplatin 85 mg/m2 day 1 
Cycled every 2 weeks for 6 months
single day MeC
FOLFOX (modified) •  Oxaliplatin 85 mg/m2 day 1 
Cycled every 2 weeks for 6 months
single day MeC
XelOX •  Oxaliplatin 130 mg/m2 day 1 
Cycled every 3 weeks for eight cycles
single day MeC
Note: Referenced with permission from the nCCn Clinical Practice guidelines in Oncology (nCCn guidelines®) for Breast Cancer V2.2011, Colon Cancer V3.2011, 
Rectal Cancer V4.2011, small Cell lung Cancer V2.2012, non-small Cell lung Cancer V3.2011 [all accessed July 11, 2011], antiemesis V1.2012 [accessed august 11, 
2011]. © national Comprehensive Cancer network, inc 2015. all rights reserved. To view the most recent and complete version of the guidelines, go online to nCCn.
org. naTiOnal COMPRehensiVe CanCeR neTWORK®, nCCn®, nCCn gUiDelines®, and all other nCCn Content are trademarks owned by the national 
Comprehensive Cancer network, inc.
Abbreviations: MeC, moderately emetogenic chemotherapy; heC, highly eC; TC, taxotere/cyclophosphamide; iV, intravenous; TaC, Docetaxel/doxorubicin/
cyclophosphomide; AC, Doxorubicin/cyclophosphomide; FAC/CAF, Flurouracil/doxorubicin/cyclophosphomide; 5-FU, 5-fluorouracil; FEC/CEF, Cyclophosphomide/
epirubicin/ Flurouracil; TCh, Docetaxel/carboplatin/trastuzumab; Ch, Docetaxel/carboplatin/trastuzumab; CT, Carboplatin/trastuzumab; CV, Cisplatin/vinorelbine; Cg, 
Cisplatin/gemicitabine; CD, Cisplatin/docetaxel; CP, Cisplatin/pemetrexed; PC, Paclitaxel/Carboplatin; Pg, Paclitaxel/Carboplatin/gemicitabine; Pe, Paclitaxel/Carboplatin/
etoposide; FOlFOX, Folinic acid/Fluorouracil/Oxaliplatin; XelOX, Capecitabine/Oxaliplatin.
